Genomic profiling of canine mast cell tumors identifies DNA copy number aberrations associated with KIT mutations and high histological grade

[1]  A. Motsinger-Reif,et al.  Association of breed and histopathological grade in canine mast cell tumours , 2017, Veterinary and comparative oncology.

[2]  M. Breen,et al.  Detection of Copy Number Imbalance in Canine Urothelial Carcinoma With Droplet Digital Polymerase Chain Reaction , 2016, Veterinary pathology.

[3]  K. Lindblad-Toh,et al.  Genome-Wide Association Study of Golden Retrievers Identifies Germ-Line Risk Factors Predisposing to Mast Cell Tumours , 2015, PLoS genetics.

[4]  E. Mauceli,et al.  Exome sequencing of lymphomas from three dog breeds reveals somatic mutation patterns reflecting genetic background , 2015, Genome research.

[5]  M. Bonkobara.  Dysregulation of tyrosine kinases and use of imatinib in small animal practice. , 2015, Veterinary journal.

[6]  Daniel M. Rotroff,et al.  Genome-wide assessment of recurrent genomic imbalances in canine leukemia identifies evolutionarily conserved regions for subtype differentiation , 2015, Chromosome Research.

[7]  V. Grieco,et al.  Comparison of 2- and 3-category histologic grading systems for predicting the presence of metastasis at the time of initial evaluation in dogs with cutaneous mast cell tumors: 386 cases (2009-2014). , 2015, Journal of the American Veterinary Medical Association.

[8]  A. Motsinger-Reif,et al.  Canine urothelial carcinoma: genomically aberrant and comparatively relevant , 2015, Chromosome Research.

[9]  S. Sabattini,et al.  Histologic Grading of Canine Mast Cell Tumor , 2015, Veterinary pathology.

[10]  P. McGreevy,et al.  Prevalence and risk factors for mast cell tumours in dogs in England , 2015, Canine Genetics and Epidemiology.

[11]  A. Motsinger-Reif,et al.  Comparative cytogenetic characterization of primary canine melanocytic lesions using array CGH and fluorescence in situ hybridization , 2014, Chromosome Research.

[12]  F. Mutinelli,et al.  Global Gene Expression Analysis of Canine Cutaneous Mast Cell Tumor: Could Molecular Profiling Be Useful for Subtype Classification and Prognostication? , 2014, PloS one.

[13]  Daniel M. Rotroff,et al.  Genomic profiling reveals extensive heterogeneity in somatic DNA copy number aberrations of canine hemangiosarcoma , 2014, Chromosome Research.

[14]  J. Warland,et al.  Breed predispositions in canine mast cell tumour: a single centre experience in the United Kingdom. , 2013, Veterinary journal.

[15]  S. Sugano,et al.  Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study. , 2013, Veterinary journal.

[16]  M. Nöthen,et al.  Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics , 2012, Immunology.

[17]  A. Motsinger-Reif,et al.  Characterization of canine osteosarcoma by array comparative genomic hybridization and RT‐qPCR: Signatures of genomic imbalance in canine osteosarcoma parallel the human counterpart , 2011, Genes, chromosomes & cancer.

[18]  M. Ellersieck,et al.  Identification of the most common cutaneous neoplasms in dogs and evaluation of breed and age distributions for selected neoplasms. , 2011, Journal of the American Veterinary Medical Association.

[19]  K. Lindblad-Toh,et al.  Refining tumor-associated aneuploidy through ‘genomic recoding’ of recurrent DNA copy number aberrations in 150 canine non-Hodgkin lymphomas , 2011, Leukemia & lymphoma.

[20]  J. Kelsey,et al.  Cutaneous MCTs: associations with spay/neuter status, breed, body size, and phylogenetic cluster. , 2011, Journal of the American Animal Hospital Association.

[21]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[22]  Kerry R Emslie,et al.  Effect of sustained elevated temperature prior to amplification on template copy number estimation using digital polymerase chain reaction. , 2011, The Analyst.

[23]  J D Webster,et al.  Proposal of a 2-Tier Histologic Grading System for Canine Cutaneous Mast Cell Tumors to More Accurately Predict Biological Behavior , 2011, Veterinary pathology.

[24]  A. Motsinger-Reif,et al.  Molecular cytogenetic characterization of canine histiocytic sarcoma: A spontaneous model for human histiocytic cancer identifies deletion of tumor suppressor genes and highlights influence of genetic background on tumor behavior , 2011, BMC Cancer.

[25]  J. Kinet,et al.  Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors. , 2010, American journal of veterinary research.

[26]  Kerry R Emslie,et al.  Comparison of methods for accurate quantification of DNA mass concentration with traceability to the international system of units. , 2010, Analytical chemistry.

[27]  C. London,et al.  Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast Cell Tumor Following Surgical Excision , 2009, Clinical Cancer Research.

[28]  C. Langford,et al.  ‘Putting our heads together’: insights into genomic conservation between human and canine intracranial tumors , 2009, Journal of Neuro-Oncology.

[29]  P. Tsai,et al.  Generation and characterization of novel canine malignant mast cell line CL1. , 2009, Veterinary immunology and immunopathology.

[30]  S. Fröhling,et al.  Chromosomal abnormalities in cancer. , 2008, The New England journal of medicine.

[31]  J. Kinet,et al.  Gain-of-Function Mutations in the Extracellular Domain of KIT Are Common in Canine Mast Cell Tumors , 2008, Molecular Cancer Research.

[32]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[33]  B. Johansson,et al.  The impact of translocations and gene fusions on cancer causation , 2007, Nature Reviews Cancer.

[34]  T. O’Brien,et al.  Evaluation of risk and clinical outcome of mast cell tumours in pug dogs. , 2006, Veterinary and comparative oncology.

[35]  J. Resau,et al.  The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. , 2006, Neoplasia.

[36]  R. Roskoski.  Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor. , 2005, Biochemical and biophysical research communications.

[37]  Cathy A. Brown,et al.  Variation among Pathologists in Histologic Grading of Canine Cutaneous Mast Cell Tumors , 2005, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc.

[38]  C. London,et al.  Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. , 2002, American journal of veterinary research.

[39]  V. Yuzbasiyan-Gurkan,et al.  Mutations in the Juxtamembrane Domain of c-KIT Are Associated with Higher Grade Mast Cell Tumors in Dogs , 2002, Veterinary pathology.

[40]  C. R. Howlett,et al.  Skin neoplasms of dogs in Sydney. , 1987, Australian veterinary journal.

[41]  E. Macewen,et al.  Canine Cutaneous Mast Cell Tumor: Morphologic Grading and Survival Time in 83 Dogs , 1984, Veterinary pathology.

[42]  J. Finnie,et al.  Skin neoplasia in dogs. , 1979, Australian veterinary journal.